| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Greenwich LifeSciences Inc. | GLSI-100 (GP2 + GM-CSF) | HER2/neu breast cancer | Phase 2b | Intracutaneous | Oncology | |
| Greenwich LifeSciences Inc. | GP2 (GLSI-100) - (FLAMINGO-01) | HER2 positive breast cancer | Phase 3 | Data Released | Intradermal | Oncology |
| GRI Bio Inc. | GRI-0621-IPF-02 | Idiopathic pulmonary fibrosis (IPF) | Phase 2a | Data Released | Oral | Respiratory |
| GRI Bio Inc. | GRI-0621-IPF-02 | Idiopathic pulmonary fibrosis (IPF) | Phase 2a | Data Released | Oral | Respiratory |
| Grifols S.A. | Prolastin-C (Alpha-1 MP) - (SPARTA) | Alpha1 Antitrypsin Deficiency (AATD) | Phase 3 | Intravenous | Genetic Disorder | |
| Gritstone bio Inc. | GRANITE-CRC-1L | 1L Microsatellite-Stable Colorectal Cancer (MSS-CRC) | Phase 2/3 | Data Released | Intravenous | Oncology |
| Gritstone bio Inc. | GRANITE-ADJUVANT | High-risk stage II/III colon cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Gritstone bio Inc. | SLATE | Non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) | Phase 2 | Ongoing | Oral | Oncology |